355 related articles for article (PubMed ID: 15301871)
21. DNA flow cytometry but not telomerase activity as predictor of disease-free survival in pT1-2/N0/G2 breast cancer.
Pinto AE; André S; Pereira T; Silva G; Soares J
Pathobiology; 2006; 73(2):63-70. PubMed ID: 16943686
[TBL] [Abstract][Full Text] [Related]
22. [Flow cytometric analysis in non-small-cell bronchial carcinoma and its prognostic significance].
Liewald F; Sunder-Plassmann L; Valet G; Wulf G; Weiss M; Schildberg FW
Chirurg; 1992 Mar; 63(3):205-10. PubMed ID: 1313755
[TBL] [Abstract][Full Text] [Related]
23. Nuclear DNA content, an adjunct to p53 and Ki-67 as a marker of resistance to radiation therapy in oral cavity and pharyngeal squamous cell carcinoma.
Raybaud H; Fortin A; Bairati I; Morency R; Monteil RA; Têtu B
Int J Oral Maxillofac Surg; 2000 Feb; 29(1):36-41. PubMed ID: 10691142
[TBL] [Abstract][Full Text] [Related]
24. Ability of bivariate cytokeratin and deoxyribonucleic acid flow cytometry to determine the biologic aggressiveness of resectable non-small cell lung cancer.
Otsuka H; Funai S; Azumi T; Hara S; Okuno K; Yasutomi M
J Thorac Cardiovasc Surg; 2002 Aug; 124(2):293-8. PubMed ID: 12167789
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
Ludovini V; Gregorc V; Pistola L; Mihaylova Z; Floriani I; Darwish S; Stracci F; Tofanetti FR; Ferraldeschi M; Di Carlo L; Ragusa M; Daddi G; Tonato M
Lung Cancer; 2004 Oct; 46(1):77-85. PubMed ID: 15364135
[TBL] [Abstract][Full Text] [Related]
26. S-phase fraction and DNA ploidy in 633 T1T2 breast cancers: a standardized flow cytometric study.
Chassevent A; Jourdan ML; Romain S; Descotes F; Colonna M; Martin PM; Bolla M; Spyratos F
Clin Cancer Res; 2001 Apr; 7(4):909-17. PubMed ID: 11309341
[TBL] [Abstract][Full Text] [Related]
27. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
28. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometric S-phase fraction as a complementary biological parameter for the cytological grading of non-Hodgkin's lymphoma.
Pinto AE; Cabeçadas J; Nóbrega SD; Mendonça E
Diagn Cytopathol; 2003 Oct; 29(4):194-9. PubMed ID: 14506670
[TBL] [Abstract][Full Text] [Related]
30. Expression level of valosin-containing protein (p97) is correlated with progression and prognosis of non-small-cell lung carcinoma.
Yamamoto S; Tomita Y; Hoshida Y; Iizuka N; Monden M; Yamamoto S; Iuchi K; Aozasa K
Ann Surg Oncol; 2004 Jul; 11(7):697-704. PubMed ID: 15231524
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of DNA ploidy status in patients with rectal cancer.
Berczi C; Bocsi J; Bartha I; Math J; Balazs G
Anticancer Res; 2002; 22(6B):3737-41. PubMed ID: 12552986
[TBL] [Abstract][Full Text] [Related]
32. Prognostic markers in resectable non-small cell lung cancer: a multivariate analysis.
Pelletier MP; Edwardes MD; Michel RP; Halwani F; Morin JE
Can J Surg; 2001 Jun; 44(3):180-8. PubMed ID: 11407827
[TBL] [Abstract][Full Text] [Related]
33. Rb and p16INK4a expression in resected non-small cell lung tumors.
Kratzke RA; Greatens TM; Rubins JB; Maddaus MA; Niewoehner DE; Niehans GA; Geradts J
Cancer Res; 1996 Aug; 56(15):3415-20. PubMed ID: 8758904
[TBL] [Abstract][Full Text] [Related]
34. Prognostic value of deoxyribonucleic acid aneuploidy in primary non-small-cell lung carcinomas and their metastases.
Liewald F; Hatz R; Storck M; Orend KH; Weiss M; Wulf G; Valet G; Sunder-Plassmann L
J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1476-82. PubMed ID: 1331622
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of Pokemon in non-small cell lung cancer and foreshowing tumor biological behavior as well as clinical results.
Zhao ZH; Wang SF; Yu L; Wang J; Chang H; Yan WL; Zhang J; Fu K
Lung Cancer; 2008 Oct; 62(1):113-9. PubMed ID: 18550205
[TBL] [Abstract][Full Text] [Related]
36. Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinoma.
Yoon BS; Kim YT; Kim S; Lee CS; Kim JW; Kim JH; Kim SW; Cho NH
Eur J Obstet Gynecol Reprod Biol; 2008 Jan; 136(1):110-5. PubMed ID: 17157431
[TBL] [Abstract][Full Text] [Related]
37. Metaphase cytogenetics and DNA flow cytometry with analysis of S-phase fraction in prostate cancer: influence on prognosis.
Bratt O; Anderson H; Bak-Jensen E; Baldetorp B; Lundgren R
Urology; 1996 Feb; 47(2):218-24. PubMed ID: 8607238
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic heterogeneity studied by immunohistochemistry and aneuploidy in non-small cell lung cancers.
Pujol JL; Simony J; Laurent JC; Richer G; Mary H; Bousquet J; Godard P; Michel FB
Cancer Res; 1989 May; 49(10):2797-802. PubMed ID: 2540908
[TBL] [Abstract][Full Text] [Related]
39. Multivariate analysis of the prognostic significance of DNA-ploidy and S-phase fraction in ovarian cancer determined by flow cytometry following detection of cytokeratin-labeled tumor cells.
Kimmig R; Wimberger P; Hillemanns P; Kapsner T; Caspari C; Hepp H
Gynecol Oncol; 2002 Jan; 84(1):21-31. PubMed ID: 11748971
[TBL] [Abstract][Full Text] [Related]
40. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
